Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $96.60 USD
Change Today +4.93 / 5.38%
Volume 567.6K
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

agios pharmaceuticals inc (AGIO) Snapshot

Open
$91.79
Previous Close
$91.67
Day High
$98.15
Day Low
$91.79
52 Week High
01/15/15 - $138.85
52 Week Low
04/4/14 - $31.42
Market Cap
3.6B
Average Volume 10 Days
716.2K
EPS TTM
$-1.59
Shares Outstanding
37.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGIOS PHARMACEUTICALS INC (AGIO)

agios pharmaceuticals inc (AGIO) Related Bloomberg News

View More Bloomberg News

agios pharmaceuticals inc (AGIO) Related Businessweek News

No Related Businessweek News Found

agios pharmaceuticals inc (AGIO) Details

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. The company’s product candidates include AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK deficiency. The company has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

128 Employees
Last Reported Date: 02/24/15
Founded in 2007

agios pharmaceuticals inc (AGIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $425.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $269.1K
Chief Operating Officer
Total Annual Compensation: $350.0K
Chief Scientific Officer
Total Annual Compensation: $376.0K
Compensation as of Fiscal Year 2013.

agios pharmaceuticals inc (AGIO) Key Developments

United States Food and Drug Administration Grants Agios Pharmaceuticals, Inc.'s Orphan Drug Designation for its Investigational Medicine AG-348

Agios Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designation for its investigational medicine AG-348 for the treatment of pyruvate kinase (PK) deficiency, a rare form of hemolytic anemia. AG-348, a first-in-class, orally available activator of pyruvate kinase-R (PKR) enzymes, met its primary endpoints in two Phase 1 healthy volunteer studies 'a single ascending dose study and multiple ascending dose study. In addition, data presented in December 2014 at the 54th Annual Meeting of the American Society of Hematology (ASH) provided early proof-of-mechanism for AG-348. Based on these findings, Agios plans to initiate a Phase 2 clinical trial in patients with PK deficiency in the first half of 2015. Based on findings presented at ASH, Agios expects to initiate a Phase 2 study of AG-348 in patients with PK deficiency in the first half of 2015. The company plans to provide final results from the Phase 1 multiple ascending dose study at a medical conference in mid-2015. A natural history study of PK deficiency is also ongoing and Agios expects to report initial data from this study at a medical conference in mid-2015.

Kevin Starr, a Board of Director of Agios Pharmaceuticals, Inc. Not to Stand for Re-Election at its 2015 Annual Meeting of Stockholders

On March 10, 2015, Kevin Starr notified Agios Pharmaceuticals, Inc. of his decision not to stand for re-election to the Board of Directors at the company when his current term expires at the company's 2015 annual meeting of stockholders. Mr. Starr will continue to serve as the chairman of the Board, a member of the Audit Committee, and the chair of the Nominating and Corporate Governance Committee until the conclusion of the 2015 annual meeting of stockholders.

Agios Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

Agios Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGIO:US $96.60 USD +4.93

AGIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGIO.
View Industry Companies
 

Industry Analysis

AGIO

Industry Average

Valuation AGIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.9x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 49.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGIOS PHARMACEUTICALS INC, please visit www.agios.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.